share_log

HC Wainwright & Co. Reiterates Buy on Ocuphire Pharma, Maintains $20 Price Target

Benzinga ·  Mar 31, 2023 06:21

HC Wainwright & Co. analyst Matthew Caufield reiterates Ocuphire Pharma (NASDAQ:OCUP) with a Buy and maintains $20 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment